Peer-reviewed veterinary case report
CHOP chemotherapy results for dogs with multicentric T-cell lymphoma
By Rebhun, R B et al.·Published in Veterinary and comparative oncology·2011·Department of Surgical and Radiological Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with multicentric T-cell lymphoma, a type of cancer affecting the lymph nodes, were treated with a chemotherapy protocol called CHOP, which includes several medications. Out of 24 dogs, 23 showed a positive response to the treatment and were able to stay on the protocol for an average of about 146 days. Overall, these dogs lived for an average of 235 days after starting treatment, with those having low platelet counts at the start living even longer. This suggests that CHOP chemotherapy can be effective for dogs with this type of lymphoma.
People also search for: dog lymphoma treatment · CHOP chemotherapy for dogs · canine cancer survival rates · multicentric T-cell lymphoma in dogs
Abstract
Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P=0.01).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21303452/